Investors Face Losses as Class Action Targets Nano-X Imaging

The complaint alleges that Nano-X overstated demand for its tomographic imaging devices while masking significant operational failures. According to the filing, the company’s production lines were poorly aligned with market needs, driving up cash burn and operating expenses. These undisclosed issues surfaced on April 20, 2026, when the company reported a $33.4 million net loss for the fourth quarter, including a $17.5 million impairment charge tied to restructuring its Korean manufacturing facility.

Following the disclosure and the departure of its Chief Financial Officer, the company's share price dropped 24.39% to close at $2.155. Shareholders looking to serve as lead plaintiff must file their motions by August 11, 2026. Robbins LLP is managing the investigation on a contingency basis, meaning participants incur no out-of-pocket legal fees.